Establishment of a yeast-based VLP platform for antigen presentation

• Main Authors: David Wetzel, Theresa Rolf, Manfred Suckow, Andreas Kranz, Andreas Barbian, Jo-Anne Chan, Joachim Leitsch, Michael Weniger, Volker Jenzelewski, Betty Kouskousis, Catherine Palmer, James G. Beeson, Gerhard Schembecker, Juliane Merz, Michael Piontek
• Format: Article
• Language: English
• Published: BMC 2018-02-01
• Series: Microbial Cell Factories
• Subjects: Virus-like particles; Chimeric virus-like particles; Antigen presentation; DHBV; Animal infectious diseases; Hansenula polymorpha
• Online Access: http://link.springer.com/article/10.1186/s12934-018-0868-0

Abstract Background Chimeric virus-like particles (VLP) allow the display of foreign antigens on their surface and have proved valuable in the development of safe subunit vaccines or drug delivery. However, finding an inexpensive production system and a VLP scaffold that allows stable incorporation of diverse, large foreign antigens are major challenges in this field. Results In this study, a versatile and cost-effective platform for chimeric VLP development was established. The membrane integral small surface protein (dS) of the duck hepatitis B virus was chosen as VLP scaffold and the industrially applied and safe yeast Hansenula polymorpha (syn. Pichia angusta, Ogataea polymorpha) as the heterologous expression host. Eight different, large molecular weight antigens of up to 412 amino acids derived from four animal-infecting viruses were genetically fused to the dS and recombinant production strains were isolated. In all cases, the fusion protein was well expressed and upon co-production with dS, chimeric VLP containing both proteins could be generated. Purification was accomplished by a downstream process adapted from the production of a recombinant hepatitis B VLP vaccine. Chimeric VLP were up to 95% pure on protein level and contained up to 33% fusion protein. Immunological data supported surface exposure of the foreign antigens on the native VLP. Approximately 40 mg of chimeric VLP per 100 g dry cell weight could be isolated. This is highly comparable to values reported for the optimized production of human hepatitis B VLP. Purified chimeric VLP were shown to be essentially stable for 6 months at 4 °C. Conclusions The dS-based VLP scaffold tolerates the incorporation of a variety of large molecular weight foreign protein sequences. It is applicable for the display of highly immunogenic antigens originating from a variety of pathogens. The yeast-based production system allows cost-effective production that is not limited to small-scale fundamental research. Thus, the dS-based VLP platform is highly efficient for antigen presentation and should be considered in the development of future vaccines.